The AGM will be held at the Thistle Inn, Thorndon at 6pm. We expect that the AGM will be brief (~15 mins) and will be followed by a speaker, Dr Paul Young MBChB, PhD, BSc (Hons), FCICM.
Members who wish can also stay for the traditional AGM dinner (also at the Thistle Inn). As usual, the dinner is strictly “pay your own way”, however it is always a great night out. For catering purposes, could members please RSVP the secretary as soon as possible so that numbers for dinner can be confirmed with the Thistle Inn. secretary.RSNZ.firstname.lastname@example.org
Clinical trials in intensive care medicine to improve the outcomes of the sickest patients in our hospitals
Dr Paul Young MBChB, PhD, BSc (Hons), FCICM.
Intensive care medicine is a relatively new medical specialty that was developed based on the simple idea of putting the sickest patients in the hospital together in one place. This place is now called the intensive care unit (ICU) and, based on their experiences caring for ICU patients, nursing and medical staff in the ICU have developed the unique set of skills that define the discipline of intensive care medicine. The ICU is where all of the patients in the hospital with an acutely life threatening medical or surgical problem that is potentially reversible are cared for. More than one in five people in New Zealand will now be treated in an ICU over their lifetime. Remarkably, although most of these people would die without the care that they receive in the ICU, more than 90% of patients admitted to an ICU in New Zealand survive. The chances of surviving an ICU admission in New Zealand are better than almost anywhere else in the world. One of the unique features of New Zealand ICUs is a very strong research focus. Over the last 10 years, New Zealand ICU clinician researchers have had more publications in the world’s highest impact medical journal, the New England Journal of Medicine, than investigators from North America and Europe combined. The story of how New Zealand ICUs developed such a strong research culture began around 25 years ago. Since then, the findings from our clinical trials have shaped the discipline of intensive care medicine and have improved the outcomes of millions of critically ill patients around the world.
About the speaker
Dr Paul Young is an intensive care specialist and clinical researcher. He is a highly recognised figure in the field of clinical ICU research internationally with more than 100 peer-reviewed publications, including multiple publications in the three highest impact medical journals in the world. He is involved in research collaborations with scientists from Australia, the UK, Canada, the USA, Italy, Scandinavia, and Brazil. Dr Young’s research has generated substantial new knowledge and has had major impact on healthcare around the world. He was awarded the Health Research Council of New Zealand’s Lily Medal in 2016 for a study evaluating intravenous fluid therapy in critically ill patients (the Lily Medal recognises an outstanding contribution to health research). He has more than $25M of current research funding including funding from peak national health research funding bodies in New Zealand, Australia, the UK, Ireland, and Canada. His focus is on the design and conduct of high quality clinical trials to improve the outcomes of critically ill patients.